With New Fund, Mitsubishi And Daiichi Sankyo Aim To Boost Japan’s Start-Ups
This article was originally published in Start Up
Daiichi Sankyo and Mitsubishi UFJ announced a modest seed fund in September, but for Japan’s academia spin-offs, the options remain limited.
You may also be interested in...
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.